Figure 1. Umbilicated and punched out papules and vesicles with yellowish and hemorrhagic crusts consistent with eczema herpeticum.
Figure 2. Tzanck test specimen of material scraped from the floor of a vesicle and stained with Wright stain revealing multinucleated giant cells (original magnification ×40). Viral cultures revealed human herpesvirus 1.
Eczema herpeticum (EH), also known by its eponym Kaposi varicelliform eruption, is a potentially fatal, widespread cutaneous infection caused by human herpesvirus 1 (HHV-1). Eczema herpeticum is characterized clinically by clusters of umbilicated vesicles and eventually pustules in areas of previously abnormal skin. The most common predisposing cutaneous disorder is atopic dermatitis. Other less commonly reported risk factors for developing EH include Wiskott-Aldrich syndrome, Darier disease, pemphigus foliaceus, benign familial chronic pemphigus, and chronic irritant contact dermatitis.1 Cases that arise from healing second-degree burns,2 autografted skin,3 and staphylococcal scalded skin syndrome4 have been reported.
Abnormal skin is the virus' portal of entry, but the eruption rapidly spreads to previously normal and uninvolved skin. The vesicles evolve into pustules and then the classic punched out erosions, which may become confluent with subsequent hemorrhagic crusting. Patients are typically febrile and appear to have had a toxic reaction.5 Visceral dissemination of HHV-1 and subsequent mortality have been estimated at 1% to 9%.6 Secondary bacterial infection often complicates the course of illness and contributes to morbidity and mortality. The most common secondary pathogen is Staphylococcus aureus.5
The incidence of EH is highest in children younger than 3 years, with an equal male-female ratio.5 Approximately 3% of all children younger than 5 years have atopic dermatitis and are at risk of developing EH.7 Restriction fragment length polymorphism studies have shown that HHV-1 strains of the F35 genotype are more often associated with EH than other HHV-1 genotypes.8 Children with atopic dermatitis who have a number of circulating natural killer cells and decreased interleukin (IL)-2 and increased IL-4 levels are more susceptible to EH.9- 10
Herein, we report the occurrence of EH 5 days after vaccination with a live, attenuated varicella vaccine. Initial evaluations raised concern whether the clinical findings were related to this. Results of the Tzanck test revealed multinucleated giant cells; however, this test cannot distinguish between HHV-1 or varicella-zoster infection. The HHV-1 infection was ultimately confirmed by conducting a viral culture. Bacterial cultures taken from the skin grew S aureus. Our patient promptly recovered after a parenteral injection of acyclovir and antistaphylococcal therapy (cephalexin oral suspension).
Neither review of all of the literature nor postmarketing surveillance by the manufacturer (Charlie A. Baechler, PhD, written communication, Merck & Co, Inc, July 25, 1997) has revealed any cases of EH after vaccination with the varicella vaccine. Adverse reactions to live, attenuated varicella vaccine include an injection site varicellalike rash with a median number of 2 lesions and a more generalized varicellalike rash with a median number of 5 lesions with the peak occurrence happening 5 to 26 days after vaccination.11
Pediatric patients with chronic cutaneous disorders are at increased risk of developing severe varicella infections, and active immunization with the varicella vaccine is not contraindicated.12 A high clinical suspicion for EH should be maintained in children with atopic dermatitis who have a vesicular eruption, even in the setting of recent varicella vaccination.
Accepted for publication December 27, 1998.
Corresponding author: Amir Bajoghli, MD, Department of Dermatology and Pediatrics, Boston University School of Medicine, 609 Albany St, Boston, MA 02118.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and
Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early
dhildhood mortality and growth failure data and their association with maternal
Thank you for submitting a comment on this article. It will be reviewed by JAMA Pediatrics editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.